This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Anne Wojcicki Regains 23andMe Control
Business acquisition

Anne Wojcicki Regains 23andMe Control

Analysis based on 14 articles · First reported Jun 13, 2025 · Last updated Jun 16, 2025

Sentiment
10
Attention
4
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of 23andMe by TTAM Research Institute, led by Anne Wojcicki, provides a resolution to the company's bankruptcy and privacy concerns, potentially stabilizing the genetic testing market. The legal challenges from New York and other states highlight ongoing regulatory scrutiny over genetic data privacy, which could influence future market practices in the biotechnology and healthcare industries.

Biotechnology Healthcare Pharmaceuticals
Event Summary

Anne Wojcicki, co-founder and former CEO of 23andMe, has successfully regained control of the genetic testing firm through her nonprofit, TTAM Research Institute. TTAM Research Institute outbid Regeneron Pharmaceuticals with a $305 million offer for 23andMe, which had filed for Chapter 11 bankruptcy in March due to declining demand and a significant 2023 data breach. The acquisition includes 23andMe's personal genome service, research services, and telehealth subsidiary Lemonaid Health. The deal is subject to approval by the United States — United States Bankruptcy Court for the Eastern District of Missouri, with a hearing scheduled for June 17. The sale has drawn legal challenges from New York and over two dozen other U.S. states, which are suing to block the potential transfer of customers' private information without consent. TTAM Research Institute has pledged to uphold 23andMe's privacy policies and comply with data protection laws, aiming to continue the company's mission while addressing customer concerns about data privacy.

Key Actions
100 TTAM Research Institute bid 23andMe
90 23andMe filed for bankruptcy
80 23andMe exposed data
70 Regeneron Pharmaceuticals offered to buy 23andMe
60 United States — New York (state) sued 23andMe
50 23andMe discontinued division
Entities Involved
stock
23andMe
23andMe, a genetic testing firm, filed for Chapter 11 bankruptcy due to declining demand and a 2023 data breach. It was acquired by TTAM Research Institute, a nonprofit led by its co-founder Anne Wojcicki, for $305 million, allowing it to continue operations under new ownership.
Importance 100.0 Sentiment 20.0
per
Anne Wojcicki
Anne Wojcicki, co-founder and former CEO of 23andMe, successfully regained control of the company through her nonprofit TTAM Research Institute, after outbidding Regeneron Pharmaceuticals in a bankruptcy auction. She aims to continue 23andMe's mission and uphold privacy policies.
Importance 100.0 Sentiment 50.0
oth
TTAM Research Institute
TTAM Research Institute, a nonprofit led by Anne Wojcicki, successfully bid $305 million to acquire 23andMe, outbidding Regeneron Pharmaceuticals. The institute has pledged to uphold 23andMe's privacy policies and comply with data protection laws.
Importance 90.0 Sentiment 50.0
stock
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals initially offered to acquire 23andMe for $256 million but was outbid by TTAM Research Institute. Regeneron declined to make a higher bid, citing its assessment of 23andMe's remaining value.
Importance 70.0 Sentiment -10.0
govactor
United States — United States Bankruptcy Court for the Eastern District of Missouri
The United States — United States Bankruptcy Court for the Eastern District of Missouri oversaw the bidding process for 23andMe's assets and is scheduled to hold a hearing on June 17 to approve the acquisition by TTAM Research Institute.
Importance 60.0 Sentiment 0.0
loc
United States — New York (state)
New York, along with over two dozen other U.S. states, filed a lawsuit against 23andMe to block the potential transfer of customers' private information without consent, raising concerns about data privacy.
Importance 40.0 Sentiment 0.0
priv
Lemonaid Health
Lemonaid Health, a telehealth program acquired by 23andMe in 2021, is included in the assets acquired by TTAM Research Institute.
Importance 20.0 Sentiment 0.0
loc
United States — Oregon
United States — Oregon's Attorney General, Dan Rayfield, expressed concerns about the sale of 23andMe's customer genetic data without explicit consent, emphasizing the sensitive nature of DNA information.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.